Tag

Biotech stocks had their worst week since 2008 last week, as stocks like Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB) and Regeneron (REGN) got hammered following Hillary Clinton’s drug-pricing tweet.

In phase 3 trials, Amgen and Allergan’s biosimilar ABP 215 proved that it works similarly to Avastin, both in terms of outcomes and reported adverse events.

Novartis AG began selling the first copy of a biotechnology drug in the U.S., offering a 15 percent discount to the original after a U.S. appeals court rejected Amgen Inc.’s last-ditch effort to protect its blockbuster cancer drug Neupogen.

A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had heart attacks. It also approved the drug for heterozygous familial...